Babcock Int'l 10-Month Overall Group Trading In Line With Expectations

Babcock International Group plc (BAB.L), on Friday, issued trading update for the first ten months of the financial year ending 31 March 2022, and said overall group trading for the period was in line with expectations.

The company noted that its new operating model is on track to deliver savings of about £20 million in this financial year. Meanwhile for fiscal 2022, the company continues to expect free cash flow to be significantly negative, reflecting material cash outflows including additional pension contributions, restructuring costs, and investments in facilities and IT upgrades.

Further, the company said it continues to "make progress on strategic priorities, including portfolio alignment." Babcock completed the sales of its UK Power business in December for gross proceeds of £50 million, and its 15.4% stake in AirTanker Holdings Ltd. in February for £95 million.

Earlier this month, the company entered into a Sales and Purchase Agreement to acquire the remaining 50% interest in our Australian Naval Ship Management joint venture for around £32 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT